Status: Sustained and Intense
The federal government's prosecution of fentanyl trafficking and distribution continues at an extraordinary pace, and with it comes sustained, high-volume demand for expert witnesses — particularly medical toxicologists and forensic pathologists — on both sides of these cases.
The numbers tell the story. In 2023, an estimated 72,776 Americans died from overdoses involving synthetic opioids (primarily illicitly manufactured fentanyl), making fentanyl the dominant driver of the nation's overdose crisis. Provisional 2024 data from the CDC shows approximately 54,743 opioid-involved overdose deaths — a 27% decline from 2023 — but fentanyl still accounted for 88% of all opioid-involved overdose deaths that year.
Each of those deaths is a potential federal or state prosecution. And each prosecution requires expert witnesses.
Key Developments
The DOJ's enforcement posture. The Department of Justice has made fentanyl enforcement a stated priority across multiple administrations. The DEA's OD Justice Task Force — a multi-agency initiative focused specifically on investigating fatal fentanyl poisonings and identifying the individuals who provided the drugs — has generated dozens of federal prosecutions. In May 2025 alone, federal prosecutors in the Central District of California announced 20 new fentanyl distribution-resulting-in-death cases filed that year under the program.
The "distribution resulting in death" charge. Prosecutors increasingly bring charges under 21 U.S.C. § 841(b)(1)(C), which provides for a mandatory minimum of 20 years when a defendant's distribution of a controlled substance results in death. These cases put causation at the center of the trial: the government must prove that the fentanyl distributed by the defendant was the *but-for cause* of the victim's death. This causation standard puts enormous weight on expert witness testimony.
The polydrug problem. Fentanyl deaths are rarely straightforward toxicology cases. The vast majority of decedents have multiple substances in their systems — alcohol, benzodiazepines, methamphetamine, cocaine, other opioids. Approximately 47% of opioid overdose deaths in 2023 also involved stimulants. This polysubstance reality creates a robust defense opportunity: if the government's medical toxicologist cannot reliably isolate fentanyl as the but-for cause given the other substances present, the prosecution's case weakens.
The analogue challenge. The proliferation of fentanyl analogues — carfentanil, acetylfentanyl, fluorofentanyl, and dozens of others — adds another layer of complexity. The Federal Analogue Act (21 U.S.C. § 813) allows prosecution for distribution of substances "substantially similar" to scheduled drugs, but proving that a novel analogue meets this standard often requires expert pharmacological testimony on potency, receptor binding, and metabolic pathways.
State-level drug-induced homicide. Many states have enacted or strengthened drug-induced homicide statutes, which allow murder or manslaughter charges against sellers whose drugs cause a buyer's death. These prosecutions mirror the federal expert witness requirements but with varying causation standards. Some states require but-for causation; others use a contributing-cause standard. The applicable standard directly affects the scope and content of expert testimony.
Where Expert Testimony Is Decisive
In a typical federal fentanyl-distribution-resulting-in-death prosecution, expert testimony is required at several critical junctures:
Cause of death determination — A forensic pathologist testifies on the autopsy findings, interpreting the cause and manner of death. In polydrug cases, the defense frequently challenges whether the pathologist can reliably attribute death to fentanyl rather than to the other substances present.
Toxicology interpretation — A medical toxicologist or forensic toxicologist testifies on the postmortem drug concentrations, their clinical significance, tolerance effects, and the pharmacokinetic interaction of multiple substances. Postmortem redistribution — where drug concentrations shift after death — is a frequent defense argument.
But-for causation — The prosecution's medical toxicologist must testify that, but for the fentanyl, the decedent would not have died. The defense's medical toxicologist testifies that the polysubstance picture makes this determination unreliable.
Analogue identification — When the substance is a fentanyl analogue, a pharmacologist may testify on whether it is "substantially similar" to scheduled fentanyl in pharmacological effect.
Expert Witness Specialties in High Demand
Medical toxicologists — The single most sought-after specialty. Board-certified medical toxicologists number approximately 500 in the United States. Not all serve as expert witnesses. Both prosecution and defense need toxicologists who can testify on causation, pharmacokinetics, lethal dose thresholds, and polysubstance scenarios.
Forensic pathologists — Performing and reviewing autopsies, determining cause and manner of death, interpreting postmortem toxicology in the context of the autopsy findings.
Forensic toxicologists (laboratory) — Testifying on analytical chemistry, testing methodology, detection limits, chain of custody for drug evidence, and the distinction between parent drugs and metabolites.
Pharmacologists — Explaining the mechanism of action of fentanyl and its analogues, receptor binding, potency comparisons, and the pharmacology of opioid overdose.
Addiction medicine specialists — Testifying on opioid use disorder, tolerance, and the clinical context in which fentanyl deaths occur — particularly relevant to defense theories about tolerance and polysubstance use.
DEA and law enforcement experts — Providing background on trafficking patterns, distribution networks, the illicit fentanyl supply chain, and the significance of drug packaging and pricing evidence.
The Supply-and-Demand Problem
Medical toxicology is a small field. The approximately 500 board-certified medical toxicologists in the United States are in demand not only from federal prosecutors and defense attorneys, but also from state prosecutors pursuing drug-induced homicide charges, civil litigators in the broader opioid MDL, and public health agencies. This is the "unicorn" dynamic that Peter George described in his 2023 post on this blog — a limited number of qualified experts, a vast number of cases, and a premium on speed and accuracy in the referral process.
References
1. CDC NCHS, "U.S. Overdose Deaths Decrease Almost 27% in 2024" (May 14, 2025) — Reporting 54,743 opioid-involved overdose deaths in 2024, down from 83,140 in 2023. 2. CDC, "About Overdose Prevention" (updated Jan. 2026) — Noting that 69% of all 2023 overdose deaths involved synthetic opioids; 47% involved both opioids and stimulants. 3. NIDA, "Drug Overdose Deaths: Facts and Figures" (Aug. 2024) — Comprehensive overdose data including 72,776 synthetic opioid deaths in 2023. 4. DEA, "Federal Prosecutors File 20 Cases This Year Against Alleged Drug Dealers Who Sold Fentanyl that Caused Fatal Drug Overdoses" (May 16, 2025) — Detailing OD Justice Task Force prosecutions in the Central District of California. 5. DOJ/USAO-SDCA, "Federal Jury Convicts San Diego Man for Fentanyl Distribution Resulting in Death" — Illustrating the role of board-certified medical toxicologist testimony in establishing but-for causation. 6. DOJ/USAO-HI, "Oahu Man Sentenced to 10 Years for Fentanyl Distribution Resulting in Death" (Dec. 2024) — Medical toxicologist testimony on fentanyl as but-for cause in polydrug case. 7. DOJ/USAO-MDPA, "Lackawanna County Man Convicted of Distribution of Fentanyl Resulting in Death" (Nov. 2024) — Prosecution using forensic pathologist, forensic toxicologist, forensic chemists, and drug trafficking expert. 8. National Association of Attorneys General, "Prosecuting Drug Overdose Cases: A Paradigm Shift" — Discussing the critical importance of consulting medical examiners and toxicologists before initiating prosecution. 9. Forensic Resources, "Death by Distribution" — Compiling resources on cause-of-death certification in drug toxicity cases, including the 2025 NAME position paper and OSAC standards. 10. USAFacts, "Are fentanyl overdose deaths rising in the US?" (Oct. 2025) — Data on fentanyl seizures, demographic breakdown of deaths, and state-level rates.
# SECTION B: Blog Posts
*These three articles follow the traditional Vident Partners blog voice — case-driven, legally substantive, written in accessible prose. They're formatted with shorter sections and subheadings to improve readability on the web and make the information easier to scan.*
